Seminars

Seminars for the The Mass Spectrometry Interest Group of the NCI at Frederick will generally be scheduled for the 2nd Tuesday of each month for 2010. A seminar is usually a 45-50 minute presentation on a topic of general interest followed by open discussion.

Meetings

Separate from the seminars, there will also be smaller meetings which will consist of a 20-30 minute presentation on a topic of specific interest followed by open discussion. Meetings will not have a regular schedule.

Seminar

Speaker: Josip Blonder, Laboratory of Proteomics and Analytical Technologies, Advanced Technology Program, SAIC-Frederick, Inc., NCI-Frederick, Frederick, Maryland 21702

Topic: "Personalized Approach to Cancer Biomarker Discovery: Application to Renal Cell Carcinoma"

Place: Building 549, Conference Room B, NCI at Frederick, Frederick, MD - Need Directions?

Time: Tuesday, March 23, 2010, at 2:00 PM

Abstract: There is growing consensus that personalized medicine may significantly improve the outcome of a patient diagnosed with cancer. Thus, proteomic approaches facilitating biomarker discovery from clinically relevant specimens are critically needed. Here we describe a personalized approach for cancer biomarker discovery that relies on subtractive shot-gun proteomics, to identify tumor-derived proteins in the plasma of a patient diagnosed with cancer. The lists of identified proteins were filtered to discover proteins that (i) were found in the tumor but not normal tissue, (ii) were identified in matching plasma, and (iii) whose spectral count was higher in tumor tissue than plasma. These filtering criteria resulted in identification of eight tumor proteins in the blood. Subsequent Western-blot analysis confirmed the presence of cadherin-5, cadherin-11, DEAD-box protein-23, and pyruvate kinase in the blood of the patient in the study as well as in the blood of four other patients diagnosed with RCC. Despite the fact that in this investigation only a single RCC tumor/patient was analyzed, the totality of findings has identified a panel of putative protein markers that now may be further investigated with high throughput techniques employing suitable immunoassays (i.e.,ELISA) or MS-assays (i.e., MRM) to test for general applicability in larger RCC patient cohorts. Finally, the concept contained within this method may accelerate the transformation of oncology from the current paradigm of categorically assigned cancer treatments derived from population-based statistics (survival functions) to evidence-based, individually targeted "personalized" treatments derived by the rational molecular profiling of an actual patient's tumor.

Jeffrey Miller, Applied Biosystems, Foster City, CA 94404
"Current Strategies for Metabolite Profiling Using Mass Spectrometry: Increasing Throughput Methods for Metabolite Screening and Identification on a Rapid Scanning Linear Ion Trap"
March 24, 2009

Robert Classon, Shimadzu Scientific Instruments, Columbia, MD
"How to Improve Your Separations by Exponentially Increasing Peak Capacity!"
May 19, 2009

Members of the Mass Spectrometry Interest Group of the NCI-Frederick
"Highlights of the 57th Annual Conference of the American Society for Mass Spectrometry (ASMS) "
June 30, 2009

Steve Fischer, Agilent Technologies, Santa Clara, CA
"Developing Software Solutions for Un-Targeted Metabolomic Research"
September 24, 2009

Kelsey Cook, National Science Foundation, Arlington, VA 22230
"Mass Spectrometry of Complex Systems - Doing It and Funding It"
November 24, 2009

Benoit Colsch, National Institute on Drug Abuse (NIDA), Baltimore, MD
"Analysis of Sialylated Glycosphingolipids in Brain Tissue Sections by Mass Spectrometry"
February 23, 2010

Josip Blonder, Laboratory of Proteomics and Analytical Technologies, SAIC-Frederick, Inc., Frederick, MD
"Personalized Approach to Cancer Biomarker Discovery: Application to Renal Cell Carcinoma"
March 23, 2010

Speaker: To be determined
Topic: To be determined